Current and future therapeutic options for COVID-19
The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:166 |
|---|---|
| Enthalten in: |
Nederlands tijdschrift voor geneeskunde - 166(2022) vom: 21. Juli |
| Sprache: |
Niederländisch |
|---|
| Weiterer Titel: |
Recente en toekomstige behandelingen bij covid-19 |
|---|
| Beteiligte Personen: |
Dankers, Marloes [VerfasserIn] |
|---|
| Themen: |
85-32-5 |
|---|
| Anmerkungen: |
Date Completed 31.08.2022 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM345541286 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345541286 | ||
| 003 | DE-627 | ||
| 005 | 20231226025305.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||dut c | ||
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345541286 | ||
| 035 | |a (NLM)36036702 | ||
| 035 | |a (PII)D6675 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dut | ||
| 100 | 1 | |a Dankers, Marloes |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current and future therapeutic options for COVID-19 |
| 246 | 3 | 3 | |a Recente en toekomstige behandelingen bij covid-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The anti-inflammatory agents dexamethasone (corticosteroid), and tocilizumab and sarilumab (IL6-inhibitors) are effective in the treatment of late COVID-19. Other anti-inflammatory agents, like anakinra (IL1-inhibitor), baricitinib and tofacitinib (JAK-inhibitors) and lenzilumab (GM-CSF-inhibitor) have also shown positive results in late COVID-19. For the treatment of early COVID-19, the inhalation corticosteroid budesonide is regarded as an off-label treatment option. Virus-inhibitors, like remdesivir, molnupiravir and nirmatrelvir/ritonavir decrease the risk of hospitalization and the development of severe COVID-19 by patients with early symptoms. Monoclonal antibodies have shown limited or no efficacy against the omicron-variant of SARS-CoV-2. Fluvoxamine, l-arginine, AT-527 and ensovibep are considered as potential promising new therapies for the treatment of early COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a AT-511 |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Phosphoramides |2 NLM | |
| 650 | 7 | |a Recombinant Fusion Proteins |2 NLM | |
| 650 | 7 | |a Guanosine Monophosphate |2 NLM | |
| 650 | 7 | |a 85-32-5 |2 NLM | |
| 650 | 7 | |a ensovibep |2 NLM | |
| 650 | 7 | |a PV6AA88RDU |2 NLM | |
| 700 | 1 | |a Nelissen-Vrancken, H Marjorie J M G |e verfasserin |4 aut | |
| 700 | 1 | |a Berger, Marjolein Y |e verfasserin |4 aut | |
| 700 | 1 | |a Bonten, Marc J M |e verfasserin |4 aut | |
| 700 | 1 | |a van Gerven, Joop M A |e verfasserin |4 aut | |
| 700 | 1 | |a Kunst, Peter W A |e verfasserin |4 aut | |
| 700 | 1 | |a Muller, Majon |e verfasserin |4 aut | |
| 700 | 1 | |a Olde Rikkert, Marcel G M |e verfasserin |4 aut | |
| 700 | 1 | |a Rosendaal, Frits R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nederlands tijdschrift voor geneeskunde |d 1946 |g 166(2022) vom: 21. Juli |w (DE-627)NLM000034231 |x 1876-8784 |7 nnns |
| 773 | 1 | 8 | |g volume:166 |g year:2022 |g day:21 |g month:07 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 166 |j 2022 |b 21 |c 07 | ||